NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Keun Seok Lee
National Cancer Center, Korea - Goyang / South Korea
Others
AD Scientific Index ID: 4606508
-
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Keun Seok Lee's MOST POPULAR ARTICLES
1-)
Trastuzumab deruxtecan in previously treated HER2-positive breast cancerS Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ...New England Journal of Medicine 382 (7), 610-621, 20209122020
2-)
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancerS Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ...New England Journal of Medicine 387 (1), 9-20, 20229212022
3-)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialD Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ...The lancet oncology 19 (7), 904-915, 20189182018
4-)
Overall survival with ribociclib plus endocrine therapy in breast cancerSA Im, YS Lu, A Bardia, N Harbeck, M Colleoni, F Franke, L Chow, J Sohn, ...New England journal of medicine 381 (4), 307-316, 20199932019
5-)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialM Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...The lancet oncology 18 (12), 1688-1700, 20176842017
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept